Dr. Chakraborty completed his Undergraduate (B.Sc) and Masters (M.Sc) degrees in India. He joined Dr. William Tansey’s laboratory at Cold Spring Harbor Laboratory for his graduate studies, and studied the importance of Myc proteolysis in blood-borne cancers. For his postdoctoral research, Dr. Chakraborty trained under Dr. William Kaelin at the Dana-Farber Cancer Institute/Harvard Medical School, studying dysregulation of oxygen-sensing pathways. As an independent investigator in the Cancer Biology Department’s GU Malignancy Research Center at the Cleveland Clinic, his work has been focused on identification of actionable targets in kidney cancer, his laboratory uses multi-disciplinary approaches, including genomic/epigenomics, metabolomics, and cell-based and in vivo animal models, in combination with high-throughput genetic and pharmacological screens, to understand how dysfunctional oxygen-sensing pathways can be exploited to identify new targetable dependencies in kidney cancer.